Calcitriol Therapy in Chronic Kidney Disease

Patient Selection and Dosing

Patients with chronic kidney disease should have a serum calcium level < 9.5 mg/dL, serum phosphorus level < 4.6 mg/dL, and elevated parathyroid hormone (PTH) levels according to the stage of chronic kidney disease before initiating calcitriol therapy, as recommended by the American Journal of Kidney Diseases 1
The initial dose of calcitriol should be carefully monitored to avoid hypercalcemia and hyperphosphatemia, with a target serum calcium level and serum phosphorus level 1

Serum calcium levels should be verified at least twice a week during the titration period, and when the optimal dose is determined, serum calcium levels should be verified monthly 1
If serum calcium levels exceed 9.5 mg/dL, calcitriol should be suspended until calcium levels normalize, then resumed at half the previous dose 1
If serum phosphorus levels exceed 4.6 mg/dL, calcitriol should be suspended, phosphate binders adjusted, and then resumed at the previous dose when phosphorus levels normalize 1

The primary adverse effects of calcitriol are hypercalcemia and hyperphosphatemia, which can cause transient or permanent deterioration of renal function 1

Patients should have a daily calcium intake of at least 600 mg, but may require lower doses or no supplement if they tend to develop hypercalcemia 1
Hemodialysis patients with PTH levels >1000 pg/mL should receive aggressive therapy with intravenous vitamin D sterols as the primary treatment, with consideration for parathyroidectomy if medical therapy fails, according to the American Journal of Kidney Diseases guidelines 1
The National Kidney Foundation's K/DOQI clinical practice guidelines recommend a target PTH range of 150-300 pg/mL for CKD patients 1
Native vitamin D deficiency can contribute to secondary hyperparathyroidism and should be corrected, as recommended by clinical guidelines 2

Calcium and phosphorus levels should be monitored every 2 weeks for the first month, then monthly, according to the American Journal of Kidney Diseases guidelines 1
PTH levels should be monitored monthly for at least 3 months, then every 3 months once target levels are achieved, as recommended by the American Journal of Kidney Diseases guidelines 1
If calcium >9.5 mg/dL, hold vitamin D therapy until calcium normalizes, then resume at half the previous dose, as per the American Journal of Kidney Diseases guidelines 1
If phosphorus >4.6 mg/dL, hold vitamin D therapy, adjust phosphate binders, then resume previous dose when phosphorus normalizes, according to the American Journal of Kidney Diseases guidelines 1

Consider parathyroidectomy when PTH persistently >800 pg/mL, associated with hypercalcemia and/or hyperphosphatemia, and refractory to medical therapy, as recommended by the American Journal of Kidney Diseases guidelines 1
Subtotal parathyroidectomy or total parathyroidectomy with autotransplantation may be considered, with preoperative imaging (99Tc-Sestamibi scan, ultrasound, CT, or MRI) recommended before re-exploration surgery, according to the American Journal of Kidney Diseases guidelines 1

Severe hyperparathyroidism (PTH >1000 pg/mL) typically requires higher doses of vitamin D sterols and longer treatment periods (>12-24 weeks), as per the American Journal of Kidney Diseases guidelines 1
Intravenous administration of vitamin D sterols is more effective than oral administration for severe hyperparathyroidism, according to the American Journal of Kidney Diseases guidelines 1
The K/DOQI clinical practice guidelines suggest holding calcitriol therapy immediately when PTH levels are severely oversuppressed, as indicated by a PTH level of 3 pg/mL, to prevent adynamic bone disease 1
When PTH rises above the target range, calcitriol can be resumed at half the previous dose, such as 0.125mcg daily or 0.25mcg every other day, according to the K/DOQI guidelines 1
If the lowest daily dose is already being used, the guidelines suggest switching to alternate-day dosing 1